CytoSorbents Corporation effected a one-for-twenty (1:20) reverse stock split of its common stock, effective September 8, 2026. The transaction was approved by shareholders at the August 13, 2026 Annual Meeting and finalized via a Certificate of Amendment filed with Delaware on September 3, 2026. Prior to the split, there were 63,022,020 shares outstanding. The split proportionally adjusted outstanding options and warrants while maintaining the $0.001 par value and total authorized share count. Fractional shares were rounded up to the nearest whole share. CytoSorbents Corporation operates in the medical device industry, specializing in blood purification technologies.

CytoSorbents Corp held its 2026 Annual Meeting of Stockholders on August 13, 2026, where shareholders approved an amendment to the Certificate of Incorporation authorizing a reverse stock split at a ratio between 1-for-5 and 1-for-20. The Board retains discretion to determine the exact ratio within this range prior to the one-year anniversary of the meeting. Additionally, five directors were elected, executive compensation was approved on an advisory basis, and WithumSmith+Brown, PC was ratified as the independent auditor. CytoSorbents Corp operates in the medical device industry, specializing in blood purification technologies.

Cytosorbents Corporation filed an 8-K to furnish its Q2 2026 earnings investor presentation. The company reported Q2 2026 revenue of $9.6 million, with gross margins improving to 73%. Operating loss narrowed by 27% to $2.6 million, and adjusted EBITDA improved by 38% to a loss of $1.6 million. Management expects operating cash flow breakeven in the second half of 2026. The presentation detailed regulatory setbacks for DrugSorb-ATR, noting an FDA denial of its De Novo application due to missing primary efficacy endpoints, though the agency indicated a new submission is possible with additional data. Cytosorbents operates in the medical device industry, developing blood purification technologies.

Cytosorbents Corporation reported financial results for the quarter ended June 30, 2026. Revenue was $9.6 million, unchanged from a year ago. Gross margin improved to 73%. Operating loss decreased by 27% to $2.6 million compared to $3.6 million in Q2 2025. Net loss was $4.4 million or $0.07 per share, versus net income of $1.9 million or $0.03 per share in the prior year period, primarily due to non-cash foreign currency translation impacts. Adjusted net loss improved by 22% to $2.8 million or $0.05 per share. Total cash and equivalents were approximately $5.9 million on June 30, 2026. The company operates in the medical technology industry, specializing in blood purification treatments for critical care and cardiac surgery.

CytoSorbents Corporation received a notice from Nasdaq stating it is not in compliance with the minimum Market Value of Listed Securities requirement, which must be at least $35 million. The company has been granted a 180-day grace period until December 28, 2026, to regain compliance. To satisfy the requirement, the market value of the common stock must meet or exceed $35 million for at least 10 consecutive business days during this period. Management is evaluating actions to restore compliance, including potentially increasing stockholders' equity to at least $2.5 million. Failure to meet the standard by the compliance date may result in delisting. CytoSorbents Corporation is a medical technology company that develops products for extracorporeal blood purification.

CytoSorbents Corporation announced at the 2026 Life Sciences Forum that it has scheduled two pre-submission meetings with the FDA in August 2026 to discuss its ticagrelor and DOAC programs. CytoSorbents Corporation is a life sciences company that develops and commercializes medical devices and pharmaceutical-based products for the treatment of extracorporeal blood purification. extracorporeal blood purification industry.